In addition, ipilimumab plus bevacizumab has been demonstrated to be correlated to downregulated tumor levels of ANG2, which may be the reason for the inhibitory effect of bevacizumab on the VEGF effect in enhancing ANG2 expression in tumors [33]. The gene discussed is ANGPT2; the disease is neoplasm.